• Like
Chemotherapy and rdiotherapy by heena mehta
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Chemotherapy and rdiotherapy by heena mehta

  • 1,207 views
Published

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
1,207
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
38
Comments
0
Likes
3

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. MEDICAL SURGICAL NURING PRESENTED BY MRS HEENA MEHTA S.Y.M.SC NURSING IVALUATION BY MR.P.YONATANSIR ASSOCIATE PROFESSER J G NURSING COLLEGE
  • 2. • INTRODUCTION OF CHEMOTHERAPY• The use of chemicals to treat cancer first began in the early 1940.The modern chemotherapy begun in 1948 with introduction of nitrogen mustard. Since that time Scientiests continued to search for medication to treat neoplasm.• , such as a virus or other microorganism.
  • 3. • DEFINITION OF CHEMOTHERAPY• The treatment of cancer using specificchemical agents ordrugs that are selectively destructive to malignant cells andtissues.• The treatment of disease using chemical agents or drugsthat are selectivelytoxic to the causative agent of thedisease, s uch as a virus or other microorganism.
  • 4. OBLECTIVES OF THECHEMOTHERAPY• *The main objective in treating patients with chemotherapy is• to maximize the death of malignant tumor cells.• * To cure the client with cancer.• * To control the tumor growth when cure is not possible.• *To extend the lifespan and improve the quality of life of client with cancer.
  • 5. HOW CHEMOTHERAPY WORKS• it is helpful to understand the normal life cycle of a cell, or the cell cycle.• All living tissue is made up of cells. Cells grow and reproduce to replace cells lost through injury or normal “wear and tear.”
  • 6. • The cell cycle is a series of steps that both normal cells and cancer cells go through in order to form new cells.• This discussion is somewhat technical, but it can help you understand how doctors predict which drugs are likely to work well together and how doctors decide how often doses of each drug should be given
  • 7. • The cell cycle has 5 phases which are labeled below using letters and numbers. Since cell reproduction happens over and over, the cell cycle is shown as a circle. All the steps lead back to the resting phase (G0), which is the starting point.• After a cell reproduces, the 2 new cells are identical. Each of the 2 cells made from the first cell can go through this cell cycle again when new cells are needed.
  • 8. • The Cell Cycle• G0 phase (resting stage): The cell has not yet started to divide. Cells spend much of their lives in this phase. Depending on the type of cell, G0 can last from a few hours to a few years. When the cell gets a signal to reproduce, it moves into the G1 phase.• G1 phase: During this phase, the cell starts making more proteins and growing larger, so the new cells will be of normal size. This phase lasts about 18 to 30
  • 9. • S phase: In the S phase, the chromosomes containing the genetic code (DNA) are copied so that both of the new cells formed will have matching strands of DNA. The S phase lasts about 18 to 20 hours.• G2 phase: In the G2 phase, the cell checks the DNA and gets ready to start splitting into 2 cells. This phase lasts from 2 to 10 hours
  • 10. • M phase (mitosis): In this phase, which lasts only 30 to 60 minutes, the cell actually splits into 2 new cells.• This cell cycle is important because many chemotherapy drugs work only on cells that are actively reproducing (not cells that are in the resting phase, G0). Some drugs specifically attack cells in a particular phase of the cell cycle (the M or S phases, for example.
  • 11. CHEMOTHERAPY DRUGS
  • 12. • Chemotherapy drugs act through a variety of mechanism but, essentially, kill cells by:• Limiting DNA synthesis and expression- By interfering with synthesis of buiding blocks for nucleic acid.
  • 13. • Cross- linking polymer DNA-Damaging the DNA template and cross-link the twostands of the double helix , preventing replication.
  • 14. • DNA double stand breaks- Bind selectively with DNA, producing complexes that block DNA replication andformation of DNA dependent RNA.• Preventing formation of mitotic apparatus- Prevent chromosome segregation at mitosisby producing metaphase arrest.
  • 15. CLASSIFICATION OF CHEMOTHERAAPY• Chemotherapeutics agents are broadly classified as:• Cell cycle-specific Drugs: Those chemotherapeutic agents that destroy cells in specific phases of the cell cycle . Most affect cells in the S-phase by interfering with DNA and RNA synthesis.
  • 16. • Cell cyle non specific Drugs:• Those chemotherapeutic agents that act independently of the cell cycle phase are termed cell cycle non- specific drugs. These drugs usually have a prolonged effect on cell , leading to cellular damage or death.
  • 17. • Chemotherapeutic agents also classifiedaccording tovarious chemical groups eachwith a different mechanism of action. These include
  • 18. 1-Alkylating agents-• Alkylating agents are so named because of their ability to alkylate many nucleophilic functional groups under conditions present in cells. They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules.• Cisplatin and carboplatin, as well as oxaliplatin, is alkylating agents.
  • 19. Polyfunctional Alkylating Drugs: Mechanism of Action• Alkyl group transfer –Major interaction: Alkylation of DNA • Primary DNA alkylation site: N7 position of guanine • interaction may involve single strands or both strands .
  • 20. –Other interactions: these drugs react with carboxyl, sulfhydryl, amino, hydroxyl, and phosphate groups of other cellular constituents–These drugs usually form a reactive intermediate – ethylene ammonium ion.
  • 21. • Polyfunctional Alkylating Drug Resistance-Increased ability to repair DNA defects-Decreased cellular permeability to the drug-Increased glutathione synthesis
  • 22. • Injection site damage (vesicant effects) and systemic toxicity.• Toxicity: – dose related – primarily affecting rapidly dividing cells • bone marrow • GI tract –nausea and vomiting within less than an hour-- with mechlorethamine, carmustine (BCNU) or cyclophosphamide
  • 23. –Emetic effects: CNS »reduced by pre- treatment with phenothiazines or cannabinoids.•gonads
  • 24. – Major Toxicity: bone marrow suppression • dose-related suppression of myelopoiesis: primary effects on –megakaryocytes –platelets –granulocytes • Bone marrow suppression is worse when alkylating agents are combined with other myelosuppressive drugs and/or radiation (dose reduction required)
  • 25. • Oral Route of Administration:cycloph osphamide (Cytoxan), melphalan (Alkeran), chlorambucil (Leukeran), busulfan (Myleran), lomustine (CCNU,CeeNU)
  • 26. • Nitrosoureas: – not cross reactive ( with respect to tumor resistance) with other alkylating drugs. –Nonenzymatic by transformation required to activate compounds. –Highly lipid- soluble-- crosses the blood-brain barrier (BBB)
  • 27. • useful in treating brain tumors–Act by cross-linking: DNA alkylation–More effective against cells in plateau phase than cells in exponential growth phase–Major route of elimination:urinary excretion–Steptozocin: • sugar-containing nitrosourea
  • 28. Other Alkylating Drugs• Procarbazine (Matulane) – Methylhydrazine derivative – Active in Hodgkins disease (combination therapy) – Teratogenic, mutagenic, leukemogenic. – Side effects: • nausea, vomiting, myelosuppression • hemolytic anemia • pulmonary effects
  • 29. • Dacarbazine (DTIC) –Clinical use: • Melanoma • Hodgkins disease • soft tissue sarcoma –Synthetic drug; requires activation by liver microsomal system.• Parenteral administration
  • 30. – Side effects: • nausea, vomiting, myelosuppression• Altretamine (Hexalen) – Clinical use: • alkylating agent-resistant: ovarian carcinoma – Activated by biotransformation (demethylation) – Side effects: • nausea, vomiting, central and peripheral nervous system neuropathies. • relatively mild myelosuppressive effects.
  • 31. • Cisplatin (Platinol) – Clinical use: • Genitourinary cancers –testicular –ovarian –bladder • In combination with bleomycin and vinblastine: curative treatment for nonseminomatous testicular cancer
  • 32. Alkylating Agent Toxicity: Summary• IV mechlorethamine, cyclophosphamide, carmustine: Nausea and Vomiting (common)• Oral cyclophosphamide: Nausea and Vomiting (less frequently)• Most Important Toxic Effect:Bone marrow suppression, leukopenia, thrombocytopenia
  • 33. –secondary to myelosuppression -- • severe infection • septicemia –hemorrhage• Cyclophosphamide (Cytoxan):alopecia, hemorrhagic cystitis (may be avoided by adequate hydration)
  • 34. 2- Anti-metabolites –• Anti-metabolites masquerade as purines ((azathioprine, mercaptopurine)) or pyrimidines—which become the building blocks of DNA. They prevent these substances from becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. They also affect RNA synthesis. Due to their efficiency, these drugs are the most widely used cytostatics
  • 35. -Tumor resistance to methotrexate: • decreased drug transport into the cell • altered dihydrofolate reductase enzyme -- lower affinity for methotrexate • decreased polyglutamate formation • quantitative increase in dihydrofolate reductase enzyme concentration in the cell (gene amplification, increased message)
  • 36. – Adverse effects: • Bone marrow suppression • Dermatologic • GI mucosa • Adverse effects reversed by leucovorin (citrovorum factor) –Leucovorin "rescue" may be used in cases of over dosage or in high- dose methotrexate protocols– Other uses: • Treatment of rheumatoid arthritis • In combination with a prostaglandin: induces abortion
  • 37. • Purine Antagonists – 6-Thiopurines (Mercaptopurine [6-MP]; Thioguanine [6-TG]) – Mercaptopurine (Purinethol) • Mechanism of Action:Activation by hypoxanthine-guanine phosphoribosyl transferase (HGPRT) to form 6-thioinosinic acid which inhibits enzymes involved in purine metabolism. (thioguanylic acid and 6- methylmercaptopurine ribotide (MMPR) also active) • Clinical Use: – childhood acute leukemia – the analog, azathioprine (Imuran)-- immunosuppressive agent.
  • 38. – Thioguanine • purine nucleotide pathway enzyme-inhibitor – decreased intracellular concentration of guanine nucleotides – inhibition of glycoprotein synthesis – Mechanism of Action: inhibits DNA/RNA synthesis• Clinical Use: – Synergistic with cytarabine in treating adult acute leukemia. – Drug resistance • Decreased HGPRT activity • In acute leukemia -- increased alkaline phosphatase, which dephosphorylates thiopurines nucleotides
  • 39. – Adverse Effects: • Both mercaptopurine and thioguanine, given orally, are excreted in the urine. – 6-MP is converted to an inactive metabolite, 6-thioruric acid, by xanthine oxidase .6-TG: requires deamination before metabolism by xanthine oxidase. – In cancer (hematologic) chemotherapy, allopurinol is used to inhibit xanthine oxidase, to prevent hyperuricemia associated with tumor cell lysis {xanthine oxidase inhibition blocks purine degradation -- purines (more soluble) are excreted instead of uric acid (less soluble)}
  • 40. use of allopurinol thus blocks acute gout and nephrotoxicity.However, the combination of allopurinol and 6- mercaptopurine, because of xanthine oxidase inhibition, can lead to mercaptopurine toxicity; This interaction does not occur with 6-TG.
  • 41. -Fludarabine phosphate • parenteral administration; renal excretion • dephosphorylated to active form: • Mechanism of Action:DNA synthesis inhibition • Clinical Use: –lymphoproliferative disease • Adverse Effect:dose-limiting -- myelosuppression.
  • 42. – Cladribine: (Leustatin) • phosphorylated by deoxycytidine kinase –incorporated into DNA –Mechanism of Action: increased strand breaks (inhibition of repair mechanisms) • Clinical Use: –Hairy cell leukemia • Adverse Effects: –Transient severe myelosuppression; possibly associated with infection.
  • 43. – Pentostatin: • irreversible inhibitor adenosine deaminase – results in toxic accumulation of deoxyadenosine nucleotides (especially in lymphocytes) • Adverse Effects: – immunosuppression (T cell mediated immunity) – myelosuppression – kidney function impairment – CNS toxicity – liver toxicity• Pyrimidine Antagonists: – Flurouracil (5-FU), normally given by IV administration (oral absorption erratic)
  • 44. • Biotransformed to ribosyl- and deoxyribosyl- derivatives. – Mechanism of Action: » One derivative, 5-fluoro-2-deoxyuridine 5- phosphate (FdUMP), inhibits thymidylate synthase and its cofactor,a tetrahydrofolate derivative, resulting in inhibition of thymidine nucleotide synthesis. » Another derivative, 5-fluorouridine triphosphate is incorporated into RNA, interfering with RNA function. » Cytotoxicity:effects on both RNA and DNA • Clinical Use: Systemically -- adenocarcinomas; Topically: skin cancer • Floxuridine (FUDR): similar to 5-FU, used for hepatic artery infusion.•
  • 45. • Major Toxicity: myelosuppression, mucositis – Cytarabine (ara-C) IV administration • Mechanism of Action:S phase-specific antimetabolite – Biotransformed to active forms: ara-CTP, competitive inhibitor of DNA polymerase. » Blocks DNA synthesis; no effect on RNA or protein synthesis – cytarabine incorporated into RNA and DNA -- interfering with chain elongation
  • 46. • Clearance: deamination (inactive form) • S phase specificity: highly schedule-dependent • Clinical Use: almost exclusively for acute myelogenous leukemia • Adverse Effects: –nausea –alopecia –stomatitis – severe myelosuppression
  • 47. – Azacitidine (IV administration): • Mechanism of Action: active derivatives inhibit orotidylate decarboxylase -- reducing pyrimidine nucleotide synthesis; azacitidine -- incorporated into DNA and RNA; inhibits DNA, RNA, and protein synthesis. • Investigational drug -- second-line agent in treatment of acute leukemia • Adverse Effect: myelosuppression.
  • 48. 3- Plant alkaloids and terpenoids .• hese alkaloids are derived from plants and block cell division by preventing microtubule function. Microtubules are vital for cell division, and, without them, cell division cannot occur. The main examples are vinca alkaloids and taxanes.
  • 49. • Vinblastine -- (Velban) – Mechanism of action: microtubule depolymerization • Mitotic arrest at metaphase; interferes with chromosome segregation – Clinical Use:: • Systemic treatment of Hodgkins disease • Lymphomas – Adverse Effects: • nausea • vomiting • alopecia • bone marrow suppression
  • 50. • Vincristine -- (Oncovin) – Mechanism of action: microtubule depolymerization • Mitotic arrest at metaphase; interferes with chromosome segregation – Clinical Use:: • In combination with prednisone: induction of remission in children with acute leukemia • useful in treating some other rapidly proliferating neoplasms – Adverse Effects: • significant frequency of neurotoxic reactions • occasional: bone marrow depression
  • 51. • Podophyllotoxins (etoposide {VP- 16}and teniposide {VM-26}) – Etoposide and teniposide: structurally similar –Mechanism of action: Block cell cycle: in late S-G2 phase • inhibition of topoisomerase II -- DNA damage –IV administration –Urinary excretion; some in bile
  • 52. – Clinical Use: • Etoposide (VP-16,VePe-sid): –monocytic leukemia –testicular cancer –oat cell lung carcinoma • Teniposide (Vumon): lymphomas– Adverse Effects: • nausea • vomiting • alopecia • significant hematopoietic toxicity and lymphoid toxicity
  • 53. • Camptothecins (topotecan and irinotecan ) – Mechanism of action: interfere with activity of topoisomerase I (cuts and religates single stranded DNA. DNA is damaged – Clinical Uses: • Topotecan: metastatic ovarian cancer -- including cisplatin-resistant forms (as effective as paclitaxel) • Adverse Effects: Topotecan -- –Primary »neutropenia »thrombocytopenia »anemia
  • 54. –Other »nausea »nominee »alopecia • Irinotecan:prodrug-metabolized active topoisomerase I inhibitor –Used in management of colon and rectal cancer, including tumors not responding to 5-FU –Adverse Effects: Irinotecan -- »Most common: diarrhea »also common: nausea, vomiting• Dose limiting adverse effect: myelosuppression
  • 55. • Taxanes (Paclitaxel (Taxol) and Docetaxel (Taxotere)) –Paclitaxel (Taxol): derivative of the Western Yew –Mitotic spindle inhibitor: enhances tubulin polymerization –Clinical Uses: • Ovarian • Advanced breast cancer
  • 56. –Dose-limiting Adverse Effects: •neutropenia •thrombocytopenia •peripheral neuropathy–Docetaxel (Taxotere):Used in advanced breast cancer •Adverse Effects:bone marrow suppression
  • 57. 4- Topoisomerase inhibitors-• Topoisomerases are enzymes our cells use to break the DNA bonds before copying and repair of breaks after copying. Topoisomerase inhibitors interfere with DNA repair causing the cancer cell to die because damaged DNA cannot be translated into proteins, such as transport and digestive proteins
  • 58. • Topoisomerase inhibitors are cell cycle specific, that is, they only kill cells that are in a particular phase of cell division and generally do not have any effect on other cells. Examples of Topoisomerase inhibitors are Etoposide and Topotecan.
  • 59. • Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase enzymes (topoisomeras e I and II), which are enzymes that control the changes in DNA structureby catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.
  • 60. • In recent years, topoisomerases have become popular targets for cancer chemotherapy treatments. It is thought that topoisomerase inhibitors block the ligation step of the cell cycle, generating single and double stranded breaks that harm the integrity of the genome. Introduction of these breaks subsequently lead to apoptosis and cell death.
  • 61. • Classification• Topoisomerase inhibitors are often divided according to which type of enzyme it inhibits.• Topoisomerase I inhibitors: irinotecan, topotecan, camptothecin and lamellarin D all target type IB topoisomerases,
  • 62. • Topoisomerase II inhibitors: etoposide (VP- 16), teniposide, doxorubicin, d aunorubicin, mitoxantrone, am sacrine, ellipticines, aurintricar boxylic acid, and HU-331, a quinolone synthesized from cannabidiol.
  • 63. • Numerous plant derived natural phenols (ex. EGCG, genistein, querc etin, resveratrol) possess strong topoisomerase inhibitory properties affecting both types of enzymes. They may express function of phytoalexins - compounds produced by plants to combat vermin and pests.
  • 64. • Use of topoisomerase inhibitors for antineoplastic treatments may lead to secondary neoplasms because of DNA damaging properties of the compounds. Also plant derived polyphenols shows signs of carcinogenity, especially in feuses and neonates who do not detoxify the compounds sufficiently.An association between high intake of tea (containing polyphenols) during pregnancy and elevated risk of childhood malignant central nervous system (CNS) tumours has been found.
  • 65. 5- Cytotoxic antibiotics-• It is bind directly toDNA , thusinhibite the synthesis of DNA and interfering with transcpition of RNA.• actinomycin ,anthracyclines,doxorubi cin• Daunorubicin,valrubicin ,epirubicin are example of antibiotics.
  • 66. Anticancer Drugs: Antibiotics• Clinically useful anticancer antibiotics: derived from Streptomyces• These antibiotics act by: – DNA intercalation, blocking synthesis of DNA and RNA• Anthracyclines: Doxorubicin (Adriamycin, Rubex, Doxil) and Daunorubicin (DaunoXome) – IV administration; hepatic metabolism; biliary excretion; some urinary excretion; enterohepatic recirculation.
  • 67. • Among the most useful anticancer antibiotics – Mechanism of action: • DNA intercalation -- blocking synthesis of DNA and RNA; DNA strands scission - - by affecting topoisomerase II • Altering membrane fluidity and ion transport • Semiquinone free radical an oxygen radical generation (may be responsible for myocardial damage)
  • 68. – Doxorubicin (Adriamycin, Rubex, Doxil)-- very important anticancer agent --• Carcinomas-Doxorubicin• breast carcinoma• ovarian carcinoma• thyroid carcinoma• endometrial carcinoma• testicular carcinoma• lung carcinoma• Sarcomas-Doxorubicin• Ewings sarcoma• osteosarcoma• rhabdomyosarcomas•
  • 69. • Hematologic Cancers-Doxorubicin• acute leukemia• multiple myeloma• Hodgkins disease• non-Hodgkins lymphoma• Adjuvant therapy in: osteogenic sarcoma and breast cancer• Generally used in combination protocols with: – cyclophosphamide (Cytoxan) – cisplatin (Platinol) – nitrosoureas
  • 70. • Major Use: Acute Leukemia• Daunorubicin: limited utility-- limited efficacy in treating solid tumors.• Idarubicin: approved for acute myeloid leukemia – Idarubicin in combination with cytarabine: more active than daunorubicin in inducing complete remission in acute myelogenous leukemia.• Adverse Effects: – Bone marrow depression (short duration) – Cumulative, dose-related, possibly irreversible cardiotoxicity. – Total, severe alopecia
  • 71. • Dactinomycin (Cosmegen) – IV administration; 50 percent remains unmetabolized. – Mechanism of action: intercalation between guanine-cytosine base pairs • inhibits DNA-dependent RNA synthesis • blocks protein synthesis – Clinical Uses: • dactinomycin in combination with vincristine (Oncovin)and surgery (may include radiotherapy) in treatment of Wilms tumor • dactinomycin with methotrexate: maybe curative for localized or disseminated gestational choriocarcinoma.
  • 72. Adverse Effects: Major dose limiting toxicity: bone marrow suppression (all blood elements affected -- particularly platelets and leukocytes) occasional severe thrombocytopenia nausea vomiting diarrhea oral ulcers Dactinomycin: immunosuppressive (patient should not receive live virus vaccines) alopecia/skin abnormalities interaction with radiation ("radiation recall")
  • 73. • Plicamycin (Mithramycin)• Mechanism of action:binds to DNA -- interrupts DNA-directed RNA synthesis –Also decreases plasma calcium (independent tumor cell action;acts on osteoclasts)• Clinical Uses: –some efficacy in testicular cancer that is unresponsive to standard treatment: –especially useful in managing severe hypercalcemia associated with cancer
  • 74. • Adverse Effects: –nausea –vomiting –thrombocytopenia –leukopenia –hypocalcemia –liver toxicity –bleeding disorders
  • 75. • Mitomycin: (Mutamycin) – Mechanism of action: • metabolic activation to produce a DNA alkylating agent. • Solid tumor hypoxic stem cells may be more sensitive to the action of mitomycin. • Best available drug, in combination with x-rays, to kill hypoxic tumor cells. – Clinical Use: • in combination chemotherapy {with vincristine and bleomycin}: squamous sell carcinoma of the cervix
  • 76. • adenocarcinoma of the stomach, pancreas, and lung {along with flurouracil and doxorubicin} • second-line drug: metastatic colon cancer • topical intravesical treatment of small bladder papillomas.– Adverse Effects: • severe myelosuppression, especially after repeated doses, suggest action on hematopoietic stem cells. • Vomiting • anorexia • occasional nephrotoxicity • occasional interstitial pneumonitis
  • 77. • Bleomycin (Blenoxane)• Mechanism of Action:binds to DNA -- produces single- and double-strand breaks (free radical formation) – Cell cycle specific: arrests division in G2 – Synergistic effects with vinblastine and cisplatin (curative protocol for testicular cancer)• Clinical Uses: – Testicular cancer – Squamous cell carcinoma: head, neck, cervix, skin, penis, and rectum
  • 78. –combination treatment: lymphoma –intracavity treatment: malignant effusions in ovarian breast cancer• Adverse Effects: –Anaphylactoid reaction (potentially fatal) –Fever –anorexia, blistering, hyperkeratosis (palms) –pulmonary fibrosis (uncommon)• No significant myelosuppression
  • 79. 6-Nitrosourceas-•It is like alkylating agents,break DNA helix.
  • 80. • Structural Features• Nitrosourea• Mechanism of Action• Hydrolysis of Nitrosourea group produces two active species• Alkylating Agents with Nitro group provides crosslinking in DNA for Chemotherapy• Carbamoylating agent O=C=N-R causing toxic effects of blocking DNA Polymerase and DNA Repair enzymes by binding to nucleophilic sites on proteins
  • 81. • Toxicity• Carbamoylating agent• Carcinogenic• Mutanogenic• Infertility• Bone marrow depression
  • 82. Agent Structure Details Indications Brain Tumor Hodgkins Lymphoma Side EffectsLomustine Delayed Myelosuppressi on Pulmonary Toxicity
  • 83. Indications Pancreatic Cancer (Beta Cells) Side Effects GLUT-2 Transporter Substrate, leading toStreptozocin lower levels of Insulin and a form of Type II Diabetes Renal Toxicity Drug interactions Doxorubicin Not a GLUT-2 Ethylchloride Transporter SubstrateChlorozotocin instead of methyl on Otherwise Per nitrosourea Streptozocin
  • 84. 7-Mitotic inhibitors-• Anti microtubule agent that interefere with mitosis act during the late G2 phse and mitosis to stabilize microtubules, thus inhibiting cell division
  • 85. Use of mitotic inhibitors in cytogenetics• Cytogenetics, the study of chromosomal material by analysis of G-Banded chromosomes, uses mitotic inhibitors extensively. In order to prepare a slide for cytogenetic study, a mitotic inhibitor is added to the cells being studied.
  • 86. • Specific agents• Taxanes• Taxanes are complex terpenes produced by the plants of the genus Taxus (yews). Originally derived from the Pacific yew tree, they are now synthesized artificially. Their principal mechanism is the disruption of the cells microtubule function by stabilizing microtubule formation. Microtubules are essential to mitotic reproduction, so through the inactivation of the microtubule function of a cell, taxanes inhibit the cells division.
  • 87. • Paclitaxel—used to treat lung cancer, ovarian cancer, breast cancer, and advanced forms of Kaposis sarcoma. [5]• Docetaxel—used to treat breast, ovarian, and non- small cell lung cancer
  • 88. • Vinca alkaloids• Vinca alkaloids are amines produced by the hallucinogenic plant Catharanthus roseus (Madagascar Periwinkle). Vinca alkaloids inhibit microtubulepolymerizat ion, thereby inhibiting mitosis.
  • 89. • Vinblastine—used to treat leukaemia, Hodgkins lymphoma, non-small cell lung cancer, breast cancer and testicular cancer. It is also a component in a large number of chemotherapy regimens.[8]• Vincristine—used to treat lymphoma, breast cancer, lung cancer, and acute lymphoblastic leukemia.[8]• Vindesine—used to treat leukaemia, lymphoma, melanoma, breast cancer, and lung cancer.[8]• Vinorelbine—used to treat breast cancer and non- small-cell lung cancer
  • 90. • Colchicine• Colchicine is an alkaloid derived from the autumn crocus (Colchicum autumnale). It inhibits mitosis by inhibiting microtubule polymerization. While colchicine is not used to treat cancer in humans, it is commonly used to treat acute attacks of gout
  • 91. • Podophyllotoxin• Podophyllotoxin and Podophyllin, derived from the may apple plant, are used to treat viral skin infections.• Griseofulvin• Griseofulvin, derived from a Penicillium mold, is an antifungal drug.
  • 92. • A mitotic inhibitor is a drug that inhibits mitosis, or cell division. These drugs disrupt microtubules, which are structures that pull the cell apart when it divides. Mitotic inhibitors are used in cancer treatment, because cancer cells are able to grow and eventually spread through the body (metastasize) through continuous mitotic division and so are more sensitive to inhibition of mitosis than normal cells
  • 93. 8-Corticosteroids-• Discrupt the cell membrain and inhibit synthesis of protein,decrease circulting lymphocytes, inhibit mitosis.
  • 94. • Discrupt the cell membrain and inhibit synthesis of protein,decrease circulting lymphocytes, inhibit mitosis.• Pharmacologic doses of steroid inhibited growth of various tumor systems. Tissue culture studies confirmed that lymphoid cells were the most sensitive to glucocorticoids, and responded to treatment with
  • 95. • ribonucleic acid (RNA), and protein synthesis. Studies of proliferating human leukemic lymphoblasts supported the hypothesis that glucocorticoids have preferential lymphocytolytic effects. The mechanism of action was initially thought to be caused by impaired energy use via decreased glucose transport and/or phosphorylation; it was later discovered that glucocorticoids induce apoptosis, or programmed cell death, in certain
  • 96. • Corticosteroids can be used to kill lymphoma, leukemia and multiple myeloma cells and may also be used to ease the side effects of other chemotherapy drugs. In addition to their chemotherapy action, corticosteroids also help reduce nausea, vomiting and allergic reactions caused by cancer treatment
  • 97. 9-Hormone therapy-•Selectively attach to estrogen receptors, cuasing downregulation of them and inhibiting tumor growth
  • 98. Anticancer Agents: Hormones• Introduction• Breast and prostatic cancer: palliation with sex hormone therapy• Adrenal corticosteroid treatment-- useful in: – acute leukemia – myeloma – lymphomas – other hematologic cancers
  • 99. • Pharmacological effects: –Steroid hormones bind to steroid receptors: –Efficacy of steroid treatment depends on specific receptor presence on malignant cell surface.• Clinical Use:Treatment of: –female and male breast cancer –prostatic cancer –endometrial cancer of uterus
  • 100. • Adverse Effects: –Fluid retention (secondary to Na-retaining properties) –Androgens-masculinization (long-term use) –Estrogens-feminization (long-term use) –Adrenocortical steroids: • hypertension • diabetes • enhanced susceptibility to infection • cushingoid appearance
  • 101. • Estrogen and Androgen Inhibitors: (Tamoxifen and Flutamide)• Tamoxifen: Breast cancer treatment –Oral administration. –Activity against progesterone- resistant endometrial neoplasm –Chemopreventive:women -- high- risk for breast cancer
  • 102. – Mechanism of Action: • Competitive partial agonist-inhibitor of estrogen • Binds to estrogen-sensitive tissues (receptors present) • Best antiestrogen effect requires minimal endogenous estrogen presence {estradiol has a much higher affinity for the estrogen receptor than tamoxifens affinity for the estrogen receptor} • Suppresses serum levels of insulin-like growth factor-1; and up-regulates local TGF-beta production. These properties may explain
  • 103. – Adverse Effects: • Generally mild • Most frequent: hot flashes • Occasionally: fluid retention, nausea– Clinical Use: • Advanced breast cancer – Most likely to be effective if: » lack endogenous estrogens {oophorectomy; postmenopausal} » Presence of cytoplasmic estrogen receptor;presence of cytoplasmic progesterone receptorColeman • Prolongs survival {surgical adjuvant therapy} in postmenopausal women with estrogen receptor-positive breast cancer.
  • 104. • Flutamide (Eulexin): prostatic cancer –Antagonizes remaining androgenic effects after orchiectomy or leuprolide treatment• Gonadotropin-Releasing Hormone Agonists (Leuprolide and Goserelin (Zoladex))• Leuprolide and goserelin: synthetic peptide analogues of gonadotropin- releasing hormone (GnRH, LHRH)
  • 105. – Mechanism of Action: Analogues more potent -- behave as GnRH agonists. • pituitary effects: when given continuously -- initial stimulation then inhibition of follicle-stimulating hormone and leutinizing hormone.• Clinical Use: treating metastatic prostate carcinoma• Comparing leuprolide with diethylstilbestrol (DES): – Similar suppression of androgens synthesis and serum prostatic acid phosphatase .
  • 106. – Adverse Effects: Leuprolide less frequently causes: • nausea • vomiting • edema • thromboembolism • painful gynecomastia–Leuprolide and goserelin: medication more costly, the more cost-effective given reduced frequency of complications.
  • 107. • Aromatase Inhibitors (Aminoglutethimide and Anastrozole (Arimidex))• Aminoglutethimide: –Mechanisms of action: Reduction in estrogen concentration • Aminoglutethimide: inhibitor of adrenal steroid synthesis ( blocks conversion of cholesterol to pregnenolone {first-step})
  • 108. • Aminoglutethimide inhibits extra-adrenal estradiol and estrone synthesis. • Aminoglutethimide inhibits an aromatase enzyme {catalyzes conversion of androstenedione to estrone} –This conversion may occur in fat.– Clinical Use: • Metastatic breast cancer (tumors contain estrogen or progesterone receptors) –Aminoglutethimide is administered with adrenalreplacement doses of hydrocortisone to ensure avoidance of adrenal insufficiency.
  • 109. » Hydrocortisone is used in preference to dexamethasone, because dexamethasone increases the degradation of aminoglutethimide. • Aminoglutethimide in combination with hydrocortisone: Second-Line Therapy for women treated with tamoxifen (aminoglutethimide causes more adverse side effects than tamoxifen)• Anastrozole (Arimidex): new, selective, nonsteroidal aromatase inhibitor. – appears to have no effect on glucocorticoid or mineralocorticoid synthesis – Clinical Use:• Treatment of advanced estrogen-or progesterone-receptor positive non-- tamoxifen responsive breast cancer
  • 110. 10-Miscellneous-• Inhibite the protein synthesis, enzymes derived from the yeast Enwinia used to deplete the supply of asparagines for leukemic cells that are dependent on exogenous source of this amino acid
  • 111. Miscellaneous Anticancer Drugs• Amsacrine: – Hepatic metabolism – Mechanism of Action: • DNA intercalation: produces single-and double-strand breaks • interaction with topoisomerase II-DNA complexes – Clinical Uses: • Anthracyclines- and cytarabine-resistant acute myelogenous leukemia • Advanced ovarian cancer • Lymphomas
  • 112. – Adverse Effects: • Does-limiting hepatic toxicity • Cardiac arrest has been noted with amsacrine infusion• Asparaginase (El-spar): – Mechanism of action: depletion of serum asparagine {forming aspartic acid and ammonia} • Decreased blood levels of asparagine and glutamine inhibit protein synthesis in those neoplastic cells that express decreased levels of asparagine synthase. • Most normal cells express sufficient levels of asparagine synthase to avoid toxicity.
  • 113. • Hydroxyurea: – Mechanism of action: • Inhibits ribonucleotide reductase; depletes deoxyribonucleoside triphosphate pools • Acts at S phase. – Clinical Uses: • Melanoma [secondary role] • Chronic myelogenous leukemia [secondary role] – Adverse Effects: • Bone marrow suppression • nausea • vomiting • diarrhea
  • 114. • Mitoxantrone (Novantrone): – Mechanism of action: • Induces DNA strand breaks • Inhibits RNA and DNA synthesis – Clinical Uses: • Refractory acute leukemia • Pediatric and adult acute myelogenous leukemia • non-Hodgkins lymphomas • breast cancer – Adverse Effects: • Dose-limiting: leukopenia • mild nausea • vomiting • stomatitis • alopecia • some cardiotoxicity {arrhythmias}
  • 115. • Mitotane (Lysodren): – Clinical Use:Single indication-- adrenal carcinoma • Reduces excessive steroid secretion – Adverse Effects: • diarrhea • mental depression • skin eruption • anorexia • nausea • somnolence • dermatitis
  • 116. • Retinoic acid Derivatives: – Clinical Uses: • Remissions -- acute promyelocytic leukemia • 13-cis-Retinoic acid: chemopreventive -- second primary tumors in patients with hand and neck squamous cell carcinoma. – Adverse Effects: • skeletal effects • hepatic effects • teratogenic effects • mucocutaneous effects
  • 117. • Bone Marrow Growth Factors (sargramostim and filgrastim): –Reduces neutropenic sepsis and other complications of chemotherapy –Filgrastim shortens neutropenic state following induction chemotherapy for acute nonlymphocytic leukemia.• Amifostine• Cytoprotective from effects of chemotherapy
  • 118. CONCEPT IN CHEMOTHERAPY• ADJUVANT CHEMOTHERAPY-• Adjuvant chemotherapy is the utilization of antineoplastics agents in additionto surgery orradiotherapy. The rationale is to destroy cancer cells left behind in the operative field or disseminated through the blood stream to metastaticlocation.
  • 119. • NEOADJUVANT CHEMOTHERAPY• It refers to the initial use of chemotherapy to reduce the bulk and lower the stage of atumor, making it amenable to cure with subsequent localtherapy.• COMBINATION CHEMOTHERAPY• It refers to the use of cytotoxic drugs in combination. It isconsistently superior to single agent therapy.
  • 120. ADMINISTRATION OF CHEMOTHERAPY• Depending on clinical setting , chemotherapy may be administered by the physician,staffnurse or specialized team ember,such as the oncology clinical nurse specialist or intravenous therapist.
  • 121. ROUTE OF ADMINISTRATION• 1-Oral• This rout is normally used for cyclophosphamide, capecitabine drugs.• 2-Intramuscular• This rout is normally used for Bleomycin drug.• 3-Intravenous-• This rout is normally used for Daxarubicine, vincristine,cisplatin, 5-fu drugs.
  • 122. • 4- Intracavitary(pleural,peritoneal) –• This rout is normally used for radioisotopes , alklying agents, methotrexate.• 5-Intrathecal• For mithotraxate and cytarabine.• 6-Intraartical-• For DTIC,5-fu, Methotraxate.• 7-Perfusion• For alkylating agents
  • 123. • 8-Continuous infusion-• For 5-fu,methotraxate and cytarabine.• 9-Subcutaneous-• For cytarabine• 10-Topical• For 5-fu crem.
  • 124. TOXIC EFFCT OF CHEMOTHERAPY• Toxicity associated with chemotherapy can be acue or chronic. Cell with rapid growth rates(e.g epithelium, bone marrow, hair follicles,and sperm) are very susceptible to damage from these agents. Varius body system may also be affected by these drugs
  • 125. GASTROINTESTINAL SYSTEM• Nausea and voming• Anorexia• Taste alteration• Weight loss• Oral mucositis• Diarrhea• Constipation
  • 126. HEMATOPIETIC SYSTEM• Leukopenia• Anemia• Thrombocytopeniautropenia• Neutopenia• Increase risk of infection and bleeding
  • 127. INTEGUMETARY SYSTEM• Alopesia• Skinreaction such as Red patches(erythema),urticaria,• hyper pigmentation in the nailbeds,• mouth or gums or teeth,Photosensitivity
  • 128. REPRODUCTIVE SYSTEM• Testicular and ovarian function impairedso result Azoospermia,oligospermia and sterility in male and• Amenorrhea,menopausal manifestations and• sterility in female with increase risk of abortion and fetal malformation.• In second and third trimester result low
  • 129. IMMUNE SYSTEM•Risk for fatal infection•Stomatitis,enteritis,gingi vitis and more infection•Fatique•Hair loss
  • 130. Damage to specific organs may occur, with resultant symptoms:• Cardiotoxicity (heart damage)• Hepatotoxicity (liver damage)• Nephrotoxicity (kidney damage)• Ototoxicity (damage to the inner ear), producing vertigo• Encephalopathy (brain dysfunction)
  • 131. Chemotherapy regimens Example of uses, and otherName Components notes AdriamycinABVD (doxorubicin), bleomycin, vin Hodgkins lymphoma blastine, dacarbazine AdriamycinAC (doxorubicin), cyclophospha Breast cancer mide Bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphaBEACOPP Hodgkins lymphoma mide, Oncovin (vincristine), procarbazine,pre dnisone Bleomycin, etoposide, Testicular cancer, germ cellBEP platinum agent (cisplatin) tumors Cyclophosphamide,CA Adriamycin (doxorubicin) Breast cancer (same as AC)
  • 132. Cyclophosphamide, AdriamycinCAF Breast cancer (doxorubicin), fluorouracil (5-FU) Cyclophosphamide,CAV Adriamycin Lung cancer (doxorubicin), vincristine Cyclophosphamide, BCNUCBV (carmustine), VP-16 Lymphoma (etoposide) Chlorambucil, vincristine (Oncovin), procarbazine, preChlVPP/EVA dnisone, etoposide, vinblasti Hodgkins lymphoma ne, Adriamycin (doxorubicin) Cyclophosphamide, hydroxydoxorubicinCHOP Non-Hodgkin lymphoma (doxorubicin), vincristine (Oncovin), prednisone
  • 133. Non-Hodgkin Cyclophosphamide, lymphoma in patients OncovinCOP or CVP with history (vincristine), predniso ofcardiovascular ne disease Cyclophosphamide, metCMF hotrexate, fluorouracil ( Breast cancer 5-FU) Cyclophosphamide, Oncovin Non-HodgkinCOPP (vincristine), procarbazi lymphoma ne, prednisone Epirubicin, cyclophosphEC Breast cancer amide Gastric Epirubicin, cisplatin, flu
  • 134. Etoposide, prednisone, Oncovin, cyclophosphEPOCH amide, Lymphomas and hydroxydaunorub icin Fluorouracil (5-FEC FU), epirubicin, cyclop Breast cancer hosphamide Fluorouracil (5-FU),FL (Also known as leucovorin (folinic Colorectal cancerMayo) acid) Fluorouracil (5-FU),FOLFOX leucovorin (folinic Colorectal cancer acid), oxaliplatin Fluorouracil (5-FU),
  • 135. High-risk progressive orICE-R ICE + rituximab recurrent lymphomas Methotrexate, bleomycin, Adriamycinm-BACOD (doxorubicin), cyclophospham Non-Hodgkin lymphoma ide, Oncovin (vincristine), dexamethasone Methotrexate, leucovorin (folinic acid), Adriamycin (doxorubicin), cyclophosphamidMACOP-B Non-Hodgkin lymphoma e, Oncovin (vincristine),prednisone, bleomy cin Mechlorethamine, OncovinMOPP (vincristine), procarbazine, pred Hodgkins lymphoma nisone methotrexate, vinblastine, adriaMVAC Advanced bladder cancer[2] mycin, cisplatin Procarbazine, CCNUPCV Brain tumors
  • 136. Prednisone, doxorubicin (a driamycin), cyclophospha mide, etoposide, cytarabineProMACE-CytaBOM Non-Hodgkin lymphoma , bleomycin, Oncovin (vincristine),methotrexate, leucovorin Rituximab, fludarabine, cycl B cell non-HodgkinR-FCM ophosphamide, mitoxantrone lymphoma Doxorubicin, mechlorethami ne, bleomycin, vinblastine, vStanford V Hodgkins lymphoma incristine, etoposide, prednis oneThal/Dex Thalidomide, dexamethasone Multiple myeloma Paclitaxel, ifosfamide, Testicular cancer, germ cellTIP platinum agent cisplatin tumors in salvage therapy Vincristine, Actinomycin, CyVAC Rhabdomyosarcoma clophosphamide
  • 137. Vincristine, AdriamycinVAD Multiple myeloma (doxorubicin), dexa methasone Hodgkins Vincristine andVAMP lymphoma, leukemi others a, multiple myeloma Vincristine, Adriamycin (doxorubicin), predn HodgkinsVAPEC-B isone, etoposide, cyc lymphoma lophosphamide, bleo mycin
  • 138. Care of the patient with chemotherapy• Before care• During care• After care
  • 139. RADIOTHERAPY• introduction• More than 60% of all clients with cancer receive radiation therapy at some point during the course of their disease Radiation therapy may be used as a primary,adjuvant or palliative treatment modality.
  • 140. • RT is the only treatment used and aims to achieve local cure of the cancer.• e.g. early stage Hodkin’s disease, skincancer and carcinoma of cervix.
  • 141. HISTORICAL BACKGROUND• X-rays were discovered in 1885 by the German physicist,Wilhelm Conrad Roentgen, alsocalled the father of diagnostic radiology.• Parallel to the discovery of X-rays, Becquerel discovered radioactivity in 1898.• During the early 1900s,radiobiological experiments were conducted.
  • 142. TYPES OF RADIATION• ionizing radiation• non-ionizing radiation• Photons (x-rays and gamma rays),• Particle radiation
  • 143. METHOD OF RADIATION• EXTERNAL RADIATION THERAPY• INTERNAL RADIATION THERAPY• A-SEALED SOURCE RADIOTHERAPY• B-UNSEALED SOURCE RADIATION THERAPY• MULTI-FIELD THERAPT• CONFORMAL RADIATION
  • 144. EXTERNAL RADIATIN THERAPY-
  • 145. A-Conformal radiotherapy
  • 146. • Conformal radiotherapy is a common type of external beam radiotherapy. It is also called 3D conformal radiotherapy (3D CRT). Conformal radiotherapy uses the same types of radiotherapy machine as standard beam external radiotherapy. But the radiotherapists put metal blocks in the path of the radiation beam. The blocks change the shape of the beam so that it ‘conforms’ more closely to the shape of the tumour.
  • 147. B-Intensity modulated radiotherapy
  • 148. • Intensity modulated radiation therapy (IMRT) uses hundreds of tiny devices called collimators to shape the radiotherapy area. The collimators also vary the intensity of the beams during each dose of treatment. The radiotherapy beams are aimed at the tumour from different directions. The collimators can move during treatment so that the machine gives very precise doses to a cancer or to specific areas within the
  • 149. C-Image guided radiotherapy
  • 150. • In image guided radiotherapy (IGRT) CT, MRI, or PET scans are taken regularly during the treatment. The scans are processed by computers to show changes in the size and position of the tumour.
  • 151. D-Tomotherapy
  • 152. • Part of the tomotherapy machine can rotate completely around the patient to take CT scans and give radiotherapy to a very localised area.
  • 153. E-Stereotactic radiotherapy and radiosurgery
  • 154. • Stereotactic radiotherapy gives radiotherapy in fewer sessions, using smaller radiation fields and higher doses than 3D conformal radiotherapy. A single treatment of this type is sometimes called radiosurgery, Gamma Knife or Cyberknife
  • 155. F- Proton therapy
  • 156. • One of the newer ways of giving radiotherapy uses a different type of radiation beam called a proton beam. Protons collect energy as they slow down and travel through the body. They then release this energy at their target point – the tumour.
  • 157. G-Electron beam radiotherapy
  • 158. • Electron beams cannot travel very far through body tissue. This type of radiotherapy is used to treatskin cancers or tumours very close to the surface of the body.
  • 159. • External radiation therapy may help relieve the problems caused by the tumors. Treatment may be done to the following body areas:
  • 160. • Head and neck• Chest:• Arms and legs:• Bones• Abdomen:• Pelvic area
  • 161. 2-INTERNAL RADIATION THERAPY
  • 162. • Internal radiotherapy is used mainly to treat cancers in the head and neck area, the cervix, womb, prostate or the skin.• Treatment is given in one of two ways:• Brachytherapy - putting solid radioactive material (the source) close to or inside the tumour for a limited period of time.• Radioisotope treatment - by using a radioactive liquid, which is given either as a drink or as an injection into a vein
  • 163. Brachytherapy
  • 164. Radioisotope therapy
  • 165. A-SEALED SOURCE RADIOTHERAPY
  • 166. • brachytherapy /brachy·ther·a· py/ (-ther´ah-pe) treatment with ionizing radiation whose source is applied to the surface of the body or within the body a short distance from the area being treated
  • 167. • Surface Applicator or "Mould" brachytherapy.• Interstitial brachytherapy.• Intracavitary brachytherapy places the sources inside a pre-existing body cavity.
  • 168. .B-UNSEALED SOURCE RADIATION THERAPY
  • 169. •Unsealed source radiotherapy relates to the use of soluble forms of radioactivesubstances which are administered to the body by injection or ingestion.
  • 170. • 1 Iodine• 2 Other unsealed sources• 3 Experimental antibody based methods - alpha emitters
  • 171. Iodine
  • 172. •• For example, iodine is an element selectively taken up by the thyroid gland in healthy people. Thyroid disease (both benign conditions like thyrotoxicosis and malignant conditions like papillarythyroid cancer) can be treated with radioactive iodine (iodine-131) which is then concentrated into the thyroid. Iodine-131 produces beta and gamma radiation.
  • 173. Other unsealed sources Isotope Use Description131I-MIBG for the treatment of phaeochromocytoma andn(metaiodobenzylguanidine) euroblastoma the main place of use of phosphorus is the bone32P for overactive bone marrow marrow89Sr 153Sm for secondary cancer in the strontium and samarium beh & bones ave just like calcium
  • 174. strontium and for secondary samarium beh89Sr cancer in the ave just like & 153Sm bones calcium radiosynovecto my in90Y the knee joint
  • 175. Experimental antibody based methods - alpha emitters• ITU work is being done on Alpha-Immunotherapy, this is an experimental method
  • 176. MULTI-FIELD THERAPY• In the planning of X-ray therapy the aim is to deliver a lethal dose to the lesion without doing significant harm to healthy tissue
  • 177. CONFORMAL RADIATION T• Three-Dimensional Conformal Radiation Therapy (3D-CRT)• Tumors are not regular; they come in different shapes and sizes. Three-dimensional conformal radiation therapy, or 3D-CRT,
  • 178. Common side effects of radiation therapy• skin problems• fatigue from lack of sleep;• Diarrhea• Nausea and vomiting• Dry mouth• Trouble swallowing• Swelling• Hair loss• Sexual problems• Urinary and bladder changes
  • 179. Site-specific side effects• Head and neck• Chest.• Stomach and abdomen• Pelvis.
  • 180. Nursing care of the patient• Before care• During care• After care